

Topic


- Cases and Deaths
- Case Rates
- Death Rates
- Syndromes
- Serogroups
- Surveillance Report


Year

2021

*Dataset version: May 2023
Final run: Jun 2, 2023*

Note: Click [here](#) to access and download Surveillance Reports.

 **Data Download**

Group A *Streptococcus* (GAS) | Group B *Streptococcus* (GBS) | *Haemophilus influenzae* (HFlu) | ***Neisseria meningitidis* (NMen)** | *Streptococcus pneumoniae* (SPN) | Bact Facts 

**Active Bacterial Core Surveillance (ABCs) Report
Emerging Infections Program Network
Neisseria meningitidis, 2021**

ABCs Areas: California (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia; Maryland; Minnesota; New Mexico; New York (15 county Rochester and Albany areas); Oregon; Tennessee (20 counties)

ABCs Population: The surveillance areas represent 45,543,010 persons. Source: Census Bureau's Vintage 2021 population estimates.

ABCs Case Definition: Disease is defined as isolation of *N. meningitidis* from a normally sterile site or detection of pathogen-specific nucleic acid in a specimen obtained from a normally sterile body site, using a validated molecular test in a resident of one of the surveillance areas.

ABCs Methodology: ABCs personnel routinely contacted microbiology laboratories serving acute care hospitals to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. Serogrouping of meningococcal isolates was done at CDC and state laboratories. Regular laboratory audits assessed completeness of active surveillance and detected additional cases. Disease rates were calculated using population estimates from the Vintage 2021 file. For national estimates of cases and deaths, race- and age-specific rates of disease were applied from the aggregate surveillance area to the age and racial distribution of the U.S. population for 49 states (excluding Oregon due to higher reported incidence rates of serogroup B and overall meningococcal disease). Oregon cases were added to obtain the national estimates. Cases with missing data, excluding ethnicity, were multiply imputed using sequential regression imputation methods.[†]

ABCs Profiles

| Race | No. | Rate* |
|-------|-----|-------|
| Black | 7 | 0.09 |
| White | 19 | 0.06 |
| Total | 29 | 0.06 |
| Other | 3 | 0.05 |

*Per 100,000 population for ABCs areas

Syndromes

| Syndrome | Cases | | Deaths | |
|--------------------------|-------|------|--------|-------|
| | No. | %* | No. | Rate† |
| Meningitis | 16 | 55.2 | 3 | 18.8 |
| Bacteremia Without Focus | 4 | 13.8 | 0 | 0.0 |

*Percent of cases
†Deaths per 100 cases with known outcome

| Serogroup | B | | C | | Y | | Other† | | |
|-----------|-------------|-----|-------|-----|-------|-----|--------|-----|-------|
| | Age (years) | No. | Rate* | No. | Rate* | No. | Rate* | No. | Rate* |
| <1 | | 3 | 0.68 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 1 | | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 2-4 | | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 5-17 | | 0 | 0.00 | 0 | 0.00 | 1 | 0.01 | 1 | 0.01 |
| 18-34 | | 0 | 0.00 | 5 | 0.05 | 0 | 0.00 | 1 | 0.01 |
| 35-49 | | 0 | 0.00 | 2 | 0.02 | 0 | 0.00 | 0 | 0.00 |
| 50-64 | | 1 | 0.01 | 2 | 0.02 | 0 | 0.00 | 0 | 0.00 |
| 65-74 | | 1 | 0.02 | 1 | 0.02 | 4 | 0.10 | 0 | 0.00 |
| 75-84 | | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| ≥85 | | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | | 5 | 0.01 | 10 | 0.02 | 5 | 0.01 | 2 | 0.00 |

*Per 100,000 population for ABCs areas (excluding Oregon)
†Other includes serogroup W and non-groupables
‡Unknown serogroup (n=3) distributed amongst known. All rates exclude Oregon. Rates including Oregon are of serogroup B: 0.01, C: 0.03, Y: 0.01, and Other: 0.00 per 100,000 population for ABCs areas.

Citation
Centers for Disease Control and Prevention. 2021. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2021. www.cdc.gov/abcs/downloads/NMEN_Surveillance_Report_2021.pdf

Rates of Meningococcal Disease in Adolescents and Young Adults†

| Serogroup | C/Y/W | | Overall | | |
|-----------|-------------|-----|---------|-----|-------|
| | Age (years) | No. | Rate* | No. | Rate* |
| 11-17 | | 0 | 0.00 | 1 | 0.03 |
| 18-22 | | 1 | 0.04 | 1 | 0.04 |

*Per 100,000 population for ABCs areas (excluding Oregon)
†Rates including Oregon are, for 11-17 year olds, overall 0.02, serogroup C/Y/W 0.00; for 18-22 year olds, overall 0.03, serogroup C/Y/W 0.03 per 100,000 population in ABCs areas.

National Estimates of Invasive Disease

Total Cases: 210 (0.06/100,000 population)
Deaths: 50 (0.02/100,000 population)
In 2021, 208 cases of meningococcal disease (confirmed and probable) were reported to the NNDSS, resulting in an incidence of 0.06/100,000 population. For more information on national incidence, view our Enhanced Meningococcal Disease Surveillance Report at <https://www.cdc.gov/meningococcal/surveillance/index.html>.

† Surveillance Note
Missing race (n=8) data were multiply imputed using sequential regression imputation methods.